Revance Therapeutics Inc. (NASDAQ:RVNC)’s share price was up 3.6% during mid-day trading on Tuesday . The company traded as high as $14.40 and last traded at $14.29, with a volume of 63,267 shares. The stock had previously closed at $13.79.

A number of equities analysts have recently issued reports on RVNC shares. Brean Capital restated a “buy” rating and set a $48.00 price objective on shares of Revance Therapeutics in a research report on Tuesday, May 24th. Zacks Investment Research downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, May 13th. Guggenheim restated a “buy” rating and set a $55.00 price objective on shares of Revance Therapeutics in a research report on Monday, April 11th. SunTrust Banks Inc. lowered their price objective on Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating for the company in a research report on Tuesday, June 14th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $35.00 price objective (down from $54.00) on shares of Revance Therapeutics in a research report on Tuesday, June 14th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $39.60.

The firm’s market capitalization is $406.78 million. The firm has a 50 day moving average price of $14.53 and a 200 day moving average price of $17.97.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.12. During the same period in the previous year, the business posted ($0.65) earnings per share. Analysts anticipate that Revance Therapeutics Inc. will post ($3.53) EPS for the current year.

Several hedge funds have recently made changes to their positions in RVNC. Jennison Associates raised its stake in shares of Revance Therapeutics by 0.8% in the third quarter. Jennison Associates now owns 78,156 shares of the biopharmaceutical company’s stock worth $2,326,000 after buying an additional 603 shares during the last quarter. Russell Frank Co purchased a new stake in shares of Revance Therapeutics during the fourth quarter worth about $1,384,000. Finally, California State Teachers Retirement System raised its stake in shares of Revance Therapeutics by 19.3% in the fourth quarter. California State Teachers Retirement System now owns 33,966 shares of the biopharmaceutical company’s stock worth $1,160,000 after buying an additional 5,492 shares during the last quarter.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.